IBRUTINIB
Manner of administration:Oral
Restriction
Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: Treatment of relapsed/refractory disease
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 5 | DPMQ: $5,357.30 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Imbruvica | |||||
Manner of administration:Oral
Restriction
Indication: Mantle cell lymphoma
Treatment phase: Initial treatment
Restriction
Indication: Mantle cell lymphoma
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 5 | DPMQ: $5,357.30 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Imbruvica | |||||
Manner of administration:Oral
Restriction
Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: Grandfather treatment - Transitioning from non-PBS to PBS-subsidised supply of first-line
therapy
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 5 | DPMQ: $5,357.30 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
Manner of administration:Oral
Restriction
Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: Initial treatment in first-line therapy (treatment cycles 1 to 3 inclusive)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 2 | DPMQ: $5,357.30 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Imbruvica | |||||
Manner of administration:Oral
Restriction
Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: Second and final continuing treatment (treatment cycles 10 to 15 inclusive) of first-line
therapy
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 4 | DPMQ: $5,357.30 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Imbruvica | |||||
Manner of administration:Oral
Restriction
Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: First continuing treatment (treatment cycles 4 to 9 inclusive) of first-line therapy
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 30 | # of repeats: 5 | DPMQ: $5,357.30 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Imbruvica | |||||